This application generally relates to the field of tissue oximetry, and more particularly, to tissue oximetry that involves using a fluorescent compound to measure oxygen concentration.
Oxygen detection is a critical element of applied wound healing research and clinical wound management and is used for both diagnostic/prognostic and therapeutic purposes. Transcutaneous oximetry (hereinafter, TCOM) is a noninvasive process that directly measures the oxygen level of tissue beneath the skin. In particular, TCOM measures the amount of oxygen that reaches the skin through blood circulation.
In conventional TCOM, an area to be tested is first prepped (e.g., cleaned, shaved). A gel that conducts electrical impulses is then applied to the area. Adhesive sensors containing electrodes that can sense oxygen are applied to the area over the gel. Electrodes in the sensors heat the area below the skin to dilate the capillaries so oxygen can flow freely to the skin, which improves the reading. The readings are converted to an electrical current and the signal is displayed on a monitor and/or recorded.
Conventional TCOM, however, have many disadvantages. For example, conventional TCOM is based on electrochemical technology, wherein electrochemical detectors are used that consume oxygen while detecting it, which results in a risk of inaccurate results. Also, oxygen tension is read on the skin at the wound periphery, instead of the more preferable location of the actual wound bed. Furthermore, the electrochemical technology requires a relatively long time (e.g., about 45 minutes) to obtain an accurate oxygen measurement. Further still, unreliable measurements can occur in the presence of lower extremity edema, which is present in all patients with venous stasis ulcers, among other disorders.
Consequently, there is a need in the art for an improved apparatus, system and method for providing TCOM.
In view of the above, it is an exemplary aspect to provide an improved apparatus, system and method for measuring oxygen concentration using TCOM.
It is another exemplary aspect to provide an apparatus, system and method for exciting and detecting oxygen-sensitive fluorescence in biological tissues.
It is still another exemplary aspect to provide an apparatus, system and method for measuring oxygen-sensitive fluorescence using a frequency domain approach.
It is an exemplary aspect to provide a wound-implantable oxygen-sensitive fluorescence probe.
It is another exemplary aspect to provide an oxygen-sensitive fluorescence probe for performing TCOM.
It is yet another exemplary aspect to use feedback from tissue oximetry to control dosage during oxygen therapy.
The above aspects and additional aspects, features and advantages will become readily apparent by describing in detail exemplary embodiments thereof with reference to the attached drawings, wherein like reference numerals denote like elements, and:
While the general inventive concept is susceptible of embodiment in many different forms, there are shown in the drawings and will be described herein in detail specific embodiments thereof with the understanding that the present disclosure is to be considered as an exemplification of the principles of the general inventive concept. Accordingly, the general inventive concept is not intended to be limited to the specific embodiments illustrated herein.
According to an exemplary embodiment, a system 100 for measuring a partial pressure of oxygen (pO2) is provided. The system 100 is based on oxygen-sensitivity of fluorescence of certain dyes. These dyes undergo modification (i.e., collisional quenching) in their excited state by molecular oxygen. In particular, if the excited dye encounters an oxygen molecule, excess energy is transferred to the oxygen molecule in a non-radiative transfer, thereby decreasing or quenching the fluorescence of the dye. The degree of quenching correlates to the level of oxygen concentration or the pO2 in the oxygen-containing media (e.g., biological tissue). As a result, an increase in pO2 decreases fluorescence intensity and lifetime with respect to the dye. Similarly, an increase in fluorescence intensity and lifetime with respect to the dye corresponds to a decrease in pO2.
The emitted fluorescence of the dye is quantitatively related to the pO2 by the Stern-Volmer equation, i.e., Equation 1.
where F0 is the fluorescence when the pO2=0, where F is the measured fluorescence at pO2, and where KSV is the Stern-Volmer constant. Thus, F0 is the unquenched fluorescence intensity and F is the fluorescence intensity for the pO2. Accordingly, if F0 and F are known, the pO2 can be determined.
Since the steady state fluorescence of the dye is dependent on its concentration, measuring an intrinsic parameter of the dye such as its fluorescence lifetime is useful. The fluorescence lifetime of the dye is quantitatively related to the pO2 by an alternative form of the Stern-Volmer equation, i.e., Equation 2.
where τ0 is the lifetime when pO2=0, where τ is the measured lifetime at pO2, and where KSV is the Stern-Volmer constant. Thus, τ0 is the unquenched lifetime and τ is the lifetime for the pO2. Accordingly, if τ0 and τ are known, the pO2 can be determined.
A direct approach for measuring the lifetime of the oxygen-sensitive dyes is to follow the rate of fluorescence decay in response to a pulse excitation. This time-domain approach, however, does not result in faster acquisition of pO2 samples.
This problem of slow acquisition times is avoided by the frequency-domain approach of the system 100. Accordingly, in the system 100, changes in fluorescence lifetimes appear as changes in the phase delay of an emission wave when the excitation is via an intensity modulated sine wave, as shown in
tan Φ=ωτ (Equation 3)
where Φ is the phase delay, where ω is the angular frequency (expressed in radians in per second), and where τ is the fluorescence lifetime of the dye for the pO2.
ω=2πf (Equation 4)
where ω is the angular frequency (expressed in radians in per second), and where f is the frequency (expressed in cycles per second).
where M is Amplitude modulation, where ω is the angular frequency (expressed in radians in per second), and where τ is the fluorescence lifetime of the dye for the pO2.
It will be appreciated that any suitable oxygen-sensitive (e.g., pO2-sensitive) dyes can be used. For example, Tris(1,10 phenatroline)ruthenium (II) (hereinafter, Ru[Phen]) is one such dye. Ru[Phen] is a fluorescent dye with an excitation wavelength (λex) of 460 nm and an emission wavelength (λem) greater than 600 nm. Several phase delay measurements were obtained using a commercial lifetime fluorometer at various modulation frequencies for Ru[Phen], as shown in
Pd-meso-tetra (4-carboxyphenyl)porphyrin (hereinafter, Pd-porphyrin), which has been used in human studies, is another exemplary dye. Pd-porphyrin is a phosphorescent dye with an excitation wavelength (λex) of 523 nm and an emission wavelength (λem) greater than 600 nm. A phase-delay vs. pO2 plot for Pd-porphyrin, which has a long lifetime, is shown in
The exemplary system 100 is shown in
The modulated output of the excitation source 102 (i.e., an excitation wave) is directed to the surface or other area of a media 106 to be measured. In an exemplary embodiment, the media 106 is a polymeric film containing a pO2-sensitive dye. The dye can be Ru[Phen], Pd-porphyrin or any other suitable dye. In another exemplary embodiment, the media 106 is a probe with a portion (e.g., a tip) of the probe containing the dye.
A filter 108 is disposed between the excitation source 102 and the media 106 to limit the excitation wavelength of the modulated output of the excitation source 102. In an exemplary embodiment, the peak excitation wavelength is 460 nm. In another exemplary embodiment, the peak excitation wavelength is 530±40 nm.
A fluorescence emission (i.e., an emission wave) leaves the media 106 at an angle (e.g., of about 60 degrees) relative to an excitation axis. A detector 110 detects the fluorescence emission from the media 106. In an exemplary embodiment, the detector 110 is a high speed avalanche photodiode.
Another filter 112 is disposed between the media 106 and the detector 110 to limit the emission wavelength. In an exemplary embodiment, the peak emission wavelength is greater than 600 nm.
A phase delay 114 between the excitation and emission waves is measured by a phase detector 116. In an exemplary embodiment, the phase detector 116 is a lock-in amplifier having a bandwidth of 120 KHz. The phase delay 114 is then transmitted to a computer 118, for example, at 1 KHz and at a resolution of 16 bits.
Exposure of the media 106 to an oxygen-deprived environment (e.g., by subjecting the media 106 to an N2 stream) leads to a rapid increase in both the phase delay 114 and an intensity of fluorescence consistent with a decrease in the extent of quenching by the loss of the oxygen. The transitions between the media 106, which contains the Ru[Phen] dye, being exposed to air (containing oxygen) and N2 (without oxygen) are illustrated in
Each time the N2 stream ends, the diffusion of oxygen into the media 106 begins immediately and results in the phase delay 114 and the intensity of fluorescence returning to their original values, which is consistent with an increase in quenching owing to the elevated oxygen levels in the media 106.
A typical phase-delay response resulting from N2-air transitions is illustrated in
In view of the exemplary system 100 described above, various apparatuses and methods can also be used for measuring pO2 based on oxygen-sensitive dyes. An exemplary device 120 (e.g., a probe) for measuring pO2, according to an exemplary embodiment, is shown in
The device 120 includes, for example, a tip 122 or other portion that contains a pO2-sensitive fluorescence dye (e.g., in film or tablet form). In an exemplary embodiment, a sensor film 124 containing the dye is located in the tip 122. In the sensor film 124 the dye is bound to silica microparticles in silicone rubber. The device 120 also includes, for example, a bifurcated fiber optic bundle forming a Y-end (not shown). One arm of the Y-end is connected to an excitation module which is described below. The other arm of the Y-end is connected to an emission module which is described below.
The position of the tip 122 of the device 120 determines the locale from which the pO2 is sensed. The device 120 can be implanted into the actual wound bed for more accurate readings.
A Silastic (a registered trademark of Dow Corning Corp.) tubing 126 surrounds the tip 122 and the fiber optic bundle. The use of the Silastic tubing 126 permits facile oxygen flux into the embedded oxygen-sensitive dye at the tip 122 of the device 120.
The bifurcated fiber optic bundle has an excitation fiber 128 at its core. Several emission fibers 130 encircle the excitation fiber 128.
Because the device 120 is intended for localization in the wound bed, the sensor film 124 is likely to undergo fouling. Accordingly, periodic replacement of the sensor film 124 may be necessary. To facilitate the replacement of the sensor film 124, it is easy to disconnect the tip 122 from the device 120 and remove the sensor film 124 at the end of the fiber optic bundle.
An exemplary device 132 (e.g., a probe) for performing TCOM, according to an exemplary embodiment, is shown in
A change in the pO2 in the sampling volume 140 is then sensed through changes in fluorescence lifetime of an oxygen-sensitive dye embedded in the sensor film 138. Such changes are measured by using an excitation source 142 (e.g., a blue LED) and detecting an emission using a detector 144, wherein the excitation source 142 and the detector 144 are held together by a detector plate 146. In an exemplary embodiment, the detector 144 is an avalanche photodiode, as shown in
The components of the device 132, 132a are held hermetically sealed in an enclosure 154. In an exemplary embodiment, the enclosure 154 is formed so as to facilitate replacement of the sensor film 138. The enclosure 154 can be light-proof and/or made of a polymeric material. The enclosure 154 can include an insulator 156 that thermally and/or electrically insulates the device 133 and 132.
The devices (e.g., devices 120, 132, 132a) are connected to an excitation module 158 and an emission module 160 to record the pO2. See
The structure of the emission module 160 is similar for both the device 120 and the device 132/132a. In the case of the wound implantable device (i.e., the device 120), the emission module 160 receives the fluorescence emission through one of the arms of the fiber optic bundle. This emission can be detected by a photomultiplier 170 with a built-in high-voltage source 172 and trans-impedance amplifier 174. The phase delay in the emission relative to the excitation can be detected by the dual phase lock-in amplifier 174. The reference for the lock-in is synched to the sine wave generator 162 of the excitation module 158.
The analog outputs of the lock-in phase delay and magnitude are sampled at a resolution of 16 bits and 1 sample per second. The digital output can then be sent to a remote computer via an embedded radio-telemetric receiver and transmitter 176. For the TCOM device, the trans-impedance amplifier 174 will be held close to the photomultiplier tube 148 or the avalanche photodiode 144, which will be part of the sensor package itself, to prevent contamination of low-level signals. The excitation module 158 and the emission module 160 facilitate high speed wound/bed oximetry.
In one exemplary embodiment, software monitors the outputs of the lock-in amplifier 174 and provides feedback control signals to a control unit of a hyperbaric chamber. In this manner, the oximetric feedback is used so that the hyperbaric chamber is automatically pressurized to the prescribed pO2. Accordingly, the oximetric feedback allows the oxygen therapy to be much more personalized.
Other exemplary functions of the software include: (1) telemetric setting of the function generator 162 and the current source 166; (2) telemetric setting of the lock-in amplifier 174 in real time; (3) providing a user interface for parameter settings and remote monitoring of pO2 and skin temperature; and (4) providing a database for archiving patient-dependent information in a secure manner.
The above description of specific embodiments has been given by way of example. From the disclosure given, those skilled in the art will not only understand the general inventive concept and its attendant advantages, but will also find apparent various changes and modifications to the structures and methods disclosed. It is sought, therefore, to cover all such changes and modifications as fall within the spirit and scope of the general inventive concept, as defined herein, and equivalents thereof. Thus, the embodiments described in the specification are only exemplary or preferred and are not intended to limit the terms of the claims in any way. The terms in the claims have all of their broad ordinary meanings and are not limited in any way or by any descriptions of these exemplary embodiments.
The present application is being filed as a non-provisional patent application claiming the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 60/749,698 filed on Dec. 13, 2005.
Number | Date | Country | |
---|---|---|---|
60749698 | Dec 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11610465 | Dec 2006 | US |
Child | 13351850 | US |